Skip to content
Back to RYTM

Rhythm Pharmaceuticals, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
51
Purchases
0
Sales
51
Purchase value
$0.00
Sale value
$37.48M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Christophe JeanDirector
4Rule 10b5-1 plan disclosed
Filed Nov 18, 2026Period of report Nov 17, 20260001649904-26-000030
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 17, 2026
Common StockF15,000$106.81$534.05K16,712Direct
SaleNov 17, 2026
Common StockF12,500$110.00$275.00K14,212Direct
SaleNov 17, 2026
Common StockF12,500$115.00$287.50K11,712Direct
Filing footnotes · 2
  1. F1The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.
  2. F2The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.
Open on SEC EDGAR
David P MeekerDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Sep 14, 2026Period of report Sep 14, 20260001649904-26-000026
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 14, 2026
Common StockF1F36,439$101.7464$655.15K282,819Direct
SaleSep 14, 2026
Common StockF1F430,746$102.347$3.15M252,073Direct
SaleSep 14, 2026
Common StockF1F58,698$103.43$899.63K243,375Direct
SaleSep 14, 2026
Common StockF1F61,817$104.5487$189.96K241,558Direct
SaleSep 14, 2026
Common StockF1F72,300$105.19$241.94K239,258Direct
Filing footnotes · 8
  1. F1The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.
  2. F2Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.
Open on SEC EDGAR
Hunter C SmithChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 1, 2026Period of report Aug 31, 20260001649904-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 31, 2026
Common StockF1F223,072$104.5871$2.41M153,726Direct
SaleAug 31, 2026
Common StockF1F311,514$105.3702$1.21M142,212Direct
SaleAug 31, 2026
Common StockF1F428,188$106.2029$2.99M114,024Direct
Filing footnotes · 5
  1. F1The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.
Open on SEC EDGAR
Joseph ShulmanChief Technical Officer
4Rule 10b5-1 plan disclosed
Filed Aug 17, 2026Period of report Aug 13, 20260001649904-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 13, 2026
Common StockF15,079$119.75$608.21K15,915Direct
Filing footnotes · 2
  1. F1The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
  2. F2The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Open on SEC EDGAR
Alastair GarfieldChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Aug 17, 2026Period of report Aug 13, 20260001649904-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 13, 2026
Common StockF1F22,007$116.1093$233.03K8,051Direct
SaleAug 13, 2026
Common StockF1F31,556$117.0759$182.17K6,495Direct
SaleAug 13, 2026
Common StockF1F43,400$118.2843$402.17K3,095Direct
SaleAug 13, 2026
Common StockF1F5800$119.1688$95.34K2,295Direct
Filing footnotes · 5
  1. F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Jennifer Kayden LeeEVP, Head of North America
4Rule 10b5-1 plan disclosed
Filed Aug 14, 2026Period of report Aug 13, 20260001649904-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 13, 2026
Common StockF175,834$117.3818$8.90M0Direct
Filing footnotes · 3
  1. F1The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
  2. F2The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
  3. F3The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Open on SEC EDGAR
Yann MazabraudEVP, Head of International
4Rule 10b5-1 plan disclosed
Filed Aug 14, 2026Period of report Aug 12, 20260001649904-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 12, 2026
Common StockF1F22,300$111.7992$257.14K110,355Direct
SaleAug 12, 2026
Common StockF1F31,000$112.856$112.86K109,355Direct
SaleAug 12, 2026
Common StockF1F43,605$114.6955$413.48K105,750Direct
SaleAug 12, 2026
Common StockF1F514,568$115.427$1.68M91,182Direct
SaleAug 12, 2026
Common StockF1F618,208$116.4941$2.12M72,974Direct
SaleAug 12, 2026
Common StockF1F717,319$117.4686$2.03M55,655Direct
Filing footnotes · 8
  1. F1The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Open on SEC EDGAR
Lynn A. TetraultDirector
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001104659-26-077305
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 22, 2026
Common StockF1F237,000$100.3215$3.71M7,000Direct
Filing footnotes · 3
  1. F1The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025.
  2. F2The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $100.00 to $100.91. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  3. F3The option is fully vested and exercisable.
Open on SEC EDGAR
Christopher Paul GermanCorporate Controller & CAO
4
Filed May 19, 2026Period of report May 15, 20260001104659-26-063830
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 15, 2026
Common Stock4,643$92.21$428.13K0Direct
Filing footnotes · 4
  1. F1Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
  2. F2The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  3. F3The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  4. F4The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Christopher Paul GermanCorporate Controller & CAO
4
Filed Mar 6, 2026Period of report Mar 4, 20260001104659-26-024750
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 4, 2026
Common StockF15,614$89.56$502.79K160Direct
Filing footnotes · 2
  1. F1Includes 21 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
  2. F2The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
Open on SEC EDGAR
Hunter C SmithChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Feb 19, 2026Period of report Feb 17, 20260001104659-26-017729
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 19, 2026
Common StockF1F61,308$100.2698$131.15K113,589Direct
SaleFeb 19, 2026
Common StockF1F71,692$100.9189$170.75K111,897Direct
SaleFeb 19, 2026
Common StockF1F8800$102.0951$81.68K111,097Direct
SaleFeb 19, 2026
Common StockF1F9585$103.2828$60.42K110,512Direct
SaleFeb 17, 2026
Common StockF1F21,200$99.415$119.30K117,266Direct
SaleFeb 17, 2026
Common StockF1F3200$100.52$20.10K117,066Direct
SaleFeb 17, 2026
Common StockF1F4900$101.70$91.53K116,166Direct
SaleFeb 17, 2026
Common StockF1F51,069$103.0024$110.11K115,097Direct
SaleFeb 17, 2026
Common StockF1200$103.84$20.77K114,897Direct
Filing footnotes · 9
  1. F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F9The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Hunter C SmithChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Feb 12, 2026Period of report Feb 10, 20260001104659-26-014546
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 12, 2026
Common StockF1F7292$96.2627$28.11K119,766Direct
SaleFeb 12, 2026
Common StockF1F8400$97.6713$39.07K119,366Direct
SaleFeb 12, 2026
Common StockF1F9800$98.9906$79.19K118,566Direct
SaleFeb 12, 2026
Common StockF1100$100.10$10.01K118,466Direct
SaleFeb 11, 2026
Common StockF1F42,266$98.37$222.91K120,558Direct
SaleFeb 11, 2026
Common StockF1F5400$99.4368$39.77K120,158Direct
SaleFeb 11, 2026
Common StockF1F6100$100.8527$10.09K120,058Direct
SaleFeb 10, 2026
Common StockF1F21,913$102.6554$196.38K123,624Direct
SaleFeb 10, 2026
Common StockF1F3700$103.6767$72.57K122,924Direct
SaleFeb 10, 2026
Common StockF1100$104.76$10.48K122,824Direct
Filing footnotes · 12
  1. F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
  2. F10Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  3. F11The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.
  4. F12The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
  5. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $$102.09 to $103.02 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.23 to $103.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.80 to $98.79 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F5The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.89 to $99.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F6The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.49 to $100.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. F7The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.04 to $96.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. F8The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.18 to $97.85 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. F9The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.54 to $99.40 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Hunter C SmithChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001104659-26-011651
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 5, 2026
Common StockF13,381$106.063$358.60K125,537Direct
SaleFeb 4, 2026
Common StockF1F21,500$104.7434$157.12K130,665Direct
SaleFeb 4, 2026
Common StockF1F31,000$106.604$106.60K129,665Direct
SaleFeb 4, 2026
Common StockF1F4747$107.6654$80.43K128,918Direct
Filing footnotes · 4
  1. F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.34 to $104.99 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.31 to $107.15 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $107.32 to $108.08 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Pamela J. CramerChief Human Resources Officer
4Rule 10b5-1 plan disclosed
Filed Dec 15, 2025Period of report Dec 11, 20250001104659-25-121181
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 11, 2025
Common StockF13,350$111.00$371.85K20,814Direct
Filing footnotes · 2
  1. F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
  2. F2The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Open on SEC EDGAR
Pamela J. CramerChief Human Resources Officer
4Rule 10b5-1 plan disclosed
Filed Nov 24, 2025Period of report Nov 20, 20250001104659-25-115421
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 20, 2025
Common StockF13,350$105.00$351.75K20,814Direct
Filing footnotes · 2
  1. F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.
  2. F2The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.